Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2004

View Archived Issues

Hypolipidemic effects of GW-707 occur via disruption of intracellular sterol trafficking

CETP and HDL: potential targets for the prevention of cardiovascular disease

Vardenafil improves erection and depression in patients with erectile dysfunction

Shire acquires U.K., Ireland marketing rights for Reminyl

Chiesi and Novartis enter Italian agreement for HFA Formoterol pMDI

Trials with Guidant's two everolimus-eluting stents begin and complete enrollment

NCI grant supports development of multiepitope cancer vaccine at Epimmune

SBIR grant funds development of discodermolide analogue production

Series C financing at Salmedix will fund pipeline progression

Screening acceptance letter for open-label extension study of Tectin

BioCurex Serum-RECAF test detects 90% of lung cancer in study

Ovation acquires North American rights for Sabril and Frisium from Aventis

Novel TNF-alpha inhibitors presented by Procter & Gamble

Lilly describes novel potent and selective 5-HT1F receptor agonists

BAY-43-9006 receives fast track status

Phase II trial of FM-VP4 meets primary endpoint

Development of NeuroVax supported by ITN grant

Pivotal phase III trial studies teduglutide for short bowel syndrome

Abbott completes acquisition of TheraSense

Remicade sBLA accepted for first-line use in early RA

BN-82002, a Cdc25 phosphatase inhibitor, supports possible target for cancer treatment

University of Pittsburgh discovers competitive Cdc25B inhibitor

Abbott's A-382535 demonstrates antiproliferative and apoptotic effects in human cancer cell lines

New antibacterial ketolides developed at Enanta

New modulators of nAchR and/or monoamine transporters claimed by NeuroSearch

Quinoline-based PARP inhibitors newly discovered at Kyorin

Novel beta2-adrenoceptor agonists and their use in respiratory disorders

New HIV protease inhibitors designed by Tibotec scientists

New prodrugs of beta-lactamase inhibitors covered by Pfizer patent